Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Feb;79(2):185-192.e1.
doi: 10.1053/j.ajkd.2021.08.005. Epub 2021 Sep 8.

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis

Ilias Bensouna  1 , Valérie Caudwell  1 , Sabah Kubab  2 , Sandra Acquaviva  1 , Agathe Pardon  1 , Nathalie Vittoz  1 , Dogan-Firat Bozman  1 , Latifa Hanafi  1 , Anne-Laure Faucon  3 , Pierre Housset  4
Affiliations
Observational Study

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis

Ilias Bensouna et al. Am J Kidney Dis. 2022 Feb.

Abstract

Rationale & objective: Recent studies showed that antibody titers after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the dialysis population are diminished as compared with the general population, suggesting the possible value of a third booster dose. We characterized the humoral response after 3 doses of the BNT162b2 vaccine in patients treated with either maintenance hemodialysis (HD) or peritoneal dialysis (PD).

Study design: Case series.

Setting & participants: 69 French patients (38 HD and 31 PD) treated at a single center who received 3 doses of the BNT162b2 vaccine.

Findings: Humoral response was evaluated using plasma levels of anti-SARS-CoV-2 spike protein S1 immunoglobulin measured after the second dose and at least 3 weeks after the third dose of the BNT162b2 vaccine. Patients (median age 68 years [interquartile range (IQR), 53-76 years], 65% men) had a median anti-S1 antibody level of 284 [IQR, 83-1190] AU/mL after the second dose, and 7,554 [IQR, 2,268-11,736] AU/mL after the third dose. Three patients were nonresponders (anti-S1 antibody level < 0.8 AU/mL), and 12 were weak responders (anti-S1 antibody level 0.8-50 AU/mL) after the second vaccine dose. After the third dose, 1 of the 3 initial nonresponders produced anti-spike antibody, and all the 12 initial weak responders increased their antibody levels. Patients with a greater increase in anti-S1 antibody levels after a third dose had lower antibody levels after the second dose, and a longer time interval between the second and the third dose. Adverse events did not seem to be more common or severe after a third vaccine dose.

Limitations: Observational study, small sample size. Relationship between antibody levels and clinical outcomes is not well understood.

Conclusions: A third dose of the BNT162b2 vaccine substantially increased antibody levels in patients receiving maintenance dialysis and appeared to be as well tolerated as a second dose.

Keywords: Antibody levels; BNT162b2; anti-spike serology; coronavirus disease 2019 (COVID-19); dialysis; end-stage renal disease (ESRD); immune response; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); third booster dose; vaccine; vaccine adverse effects.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Study flowchart. Abbreviations: HD, hemodialysis; peritoneal dialysis.
Figure 2
Figure 2
Humoral response after the second and the third vaccine doses. Abbreviations: Ab, antibody; AU, arbitrary unit.
Figure 3
Figure 3
Anti-spike antibody increase after the third vaccine dose according to the delay between the second and the third vaccine doses, and anti-spike antibody level after the second vaccine dose. Abbreviation: Ab, antibody.
Figure 4
Figure 4
Self-reported (left panel) reactions to vaccine after the third dose and (right panel) overall tolerance of the third vaccine dose.
See this image and copyright information in PMC

Comment in

References

    1. Shimada N., Shimada H., Itaya Y., Tomino Y. Novel coronavirus disease in patients with end-stage kidney disease. Ther Apher Dial. 2021;25(5):544–550. doi: 10.1111/1744-9987.13599. - DOI - PMC - PubMed
    1. Meziyerh S., Helm D., Vries A.P.J. Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience. Transpl Int. 2020;33(11):1557–1561. doi: 10.1111/tri.13714. - DOI - PMC - PubMed
    1. Nikoskelainen J., Koskela M., Forsström J., Kasanen A., Leinonen M. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int. 1985;28(4):672–677. doi: 10.1038/ki.1985.182. - DOI - PubMed
    1. Pitchou Y Kengibe, Jean-Robert R Makulo, Yannick M Nlandu, et al. Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study. Pan Afr Med J. 2019;34:122. doi: 10.11604/pamj.2019.34.122.19603. - DOI - PMC - PubMed
    1. Crépin T., Legendre M., Courivaud C., et al. Premature immune senescence and chronic kidney disease: update and perspectives. Article in French. Nephrol Ther. 2020;16(1):9–18. doi: 10.1016/j.nephro.2019.04.005. - DOI - PubMed

Publication types